GET YOUR EMAIL UPDATES

Dear Breakeros, welcome to the website of the largest psychedelic conference in the known universe. Please sign up to our Breaking Convention newsletter for irregular updates about our events and publications.

Secure and Spam free...

SPEAKERS

img
MICHAEL BOGENSCHUTZ MD
Research Professor of Psychiatry

Dr. Bogenschutz is Research Professor of Psychiatry at NYU Langone Medical Center. Prior to joining the faculty of NYU in June 2015, he served as Professor of Psychiatry and Psychology, Vice-Chair and Division Director for Addiction Psychiatry, and Vice Chair for Clinical Research in the Department of Psychiatry at the University of New Mexico Health Sciences Center. For 10 years he was Principal Investigator of the Southwest Node of the National Institute on Drug Abuse Clinical Trials Network. He founded and was formerly director of the addiction psychiatry fellowship program at UNM, and has extensive experience in mentoring junior investigators. Dr. Bogenschutz’s research interests focus on development of novel combinations of pharmacologic and psychosocial therapies to improve outcomes in patients with alcohol and other drug addictions, the integration of addictions treatment into medical settings, and the treatment of co-occurring psychiatric and addictive disorders. He is particularly focused on the development of psychedelic medicines for the treatment of addictions and other psychiatric and behavioral conditions. He is currently conducting a phase II randomized double-blind controlled trial of psilocybin-assisted treatment of alcohol use disorder.

Bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.bogenschutz.1/bibliography/40347689/public/?sort=date&direction=ascending

ABSTRACT


My talk will provide an overview and update on psychedelic-assisted treatment of addiction, with a focus on recent work with psilocybin in alcohol use disorder. Alcoholism was the most-studied indication for psychedelic therapy in the 1950s and 1960s. Although the controlled trials of that era had limitations, LSD was shown to lead to clinically significant benefit when the results of these studies were pooled in a meta-analysis many years later. Psilocybin-assisted treatment has recently been shown result in significant improvement in uncontrolled proof-of-concept studies addressing alcohol and nicotine dependence. We are currently conducting a full-scale double-blind randomized controlled trial of psilocybin-assisted treatment of alcohol use disorder. I will discuss the design of this study, experience with study participants, and current hypotheses concerning the possible mechanisms of action of psilocybin-assisted treatment.